Intervention not reported
Treatment‐related mortality · Participants with PCNSL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events: treatment‐related neurotoxicity · Participants with PCNSL
It is very uncertain whether the intervention changes adverse events: treatment‐related neurotoxicity (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: delayed neurotoxicity · Participants with PCNSL
1 finding from 1 review
Intervention not reported
Quality of life · Participants with PCNSL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with haematological malignancies
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Distress at · participants with haematological malignancies
It is very uncertain whether yoga in addition to standard care changes distress Scale from: 0 to 75. Higher scores indicate a more severe… compared with standard care only (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Fatigue · participants with haematological malignancies
It is very uncertain whether yoga in addition to standard care changes fatigue Scale from: 0 to 10. Higher scores indicate a higher level… compared with standard care only (very low certainty).
1 finding from 1 review
MD 0
Studies not reported
Very low
Anxiety · participants with haematological malignancies
It is very uncertain whether yoga in addition to standard care changes anxiety Scale from: 20 to 80. Higher scores indicate higher levels… compared with standard care only (very low certainty).
1 finding from 1 review
MD 0.3
Studies not reported
Very low
Depressive symptoms · participants with haematological malignancies
It is very uncertain whether yoga in addition to standard care changes depression Scale from: 0 to 60. Higher scores indicate more… compared with standard care only (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Quality of sleep · participants with haematological malignancies
It is very uncertain whether yoga in addition to standard care changes quality of sleep Scale from: 0 to 21. Higher scores indicate a lower… compared with standard care only (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse events · participants with haematological malignancies
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · participants with haematological malignancies
BMT showed no clear difference in mortality compared with PBSCT (high certainty).
1 finding from 1 review
Relapse, progression or death (calculated instead of PFS) · participants with haematological malignancies
BMT showed no clear difference in progress, relapse or death compared with PBSCT (moderate certainty).
1 finding from 1 review
Non relapse or transplant related mortality · participants with haematological malignancies
BMT showed no clear difference in non relapse or transplant related mortality compared with PBSCT (high certainty).
1 finding from 1 review
Chronic GVHD (extensive) · participants with haematological malignancies
BMT probably leads to lower extensive chronic GvHD compared with PBSCT (moderate certainty).
1 finding from 1 review
Acute GvHD III to IV · participants with haematological malignancies
BMT showed no clear difference in acute GvHD III to IV compared with PBSCT (moderate certainty).
1 finding from 1 review
Chronic GvHD overall · participants with haematological malignancies
BMT probably leads to lower chronic GvHD overall compared with PBSCT (moderate certainty).
1 finding from 1 review
Acute GVHD II to IV · participants with haematological malignancies
BMT showed no clear difference in acute GvHD II to IV compared with PBSCT (moderate certainty).
1 finding from 1 review
Overall survival · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in overall survival compared with methotrexate (low certainty).
1 finding from 1 review
Prevention of acute GVHD grade II to IV · people receiving allogeneic hematopoietic stem cell transplantation
It is very uncertain whether mycophenolate mofetil changes prevention of acute GVHD grade II to IV compared with methotrexate (very low certainty).
1 finding from 1 review